Diversity One Year Later: How Pharmaceutical Companies Can Plan Their Diversity Strategies Now

Diversity One Year Later: How Pharmaceutical Companies Can Plan Their Diversity Strategies Now

Webinar

On Demand Webinar: Diversity one year later: How pharmaceutical companies can plan their diversity strategies now
Duration: 45 mins

The US FDA issued their updated draft guidance for the industry on developing plans to increase racial and ethnic diversity in clinical trials. How have pharmaceutical companies changed their clinical trial strategies since then, and how can they set themselves up for success?

Join this on demand event where we discuss regulators’ growing expectations of pharmaceutical companies around diversity, and the state of diversity in clinical trials today. We share steps to take to optimize selection of sites that will enroll diverse populations and more confidently set up diversity goals and action plans for clinical trials.

You will learn:

  • What new regulations, including the Consolidated Appropriation Act, 2023, means for diversity requirements in clinical trials
  • How to build an evidence-based diversity action plan for FDA submission
  • What data and insights you can leverage to achieve greater enrollment of diverse populations

Speakers:

Ted Bebi, Medidata Product Strategy & Innovation Manager

Ted Bebi is a Product Strategy & Innovation Manager at Medidata AI focusing on the Diversity Module in Intelligent Trials. He has experience in clinical trial data and RWD from his work with Medidata as well as his prior role as a research scientist for Astrazeneca. He holds a BA from Macalester College where he studied Biology and Applied Math.


Fiona Maini, Medidata Sr. Director Global Compliance and Strategy

A global program director with a sustained record of successfully delivering key strategic and operational excellence programs for pharmaceutical and regulatory clients. Fiona is a member of the EU Artificial Intelligence Alliance and Chair of the ACRO Working Party on Virtual Trials.

Who Should Attend:

  • Chief Diversity Officers (whose mandate includes assessing and improving diversity within the organization)
  • Clinical Development Directors
  • Clinical Operations Directors
  • Study feasibility Directors
  • Trial planning Managers